Sequential single-agent obatoclax mesylate (GX15–070MS) followed by combination with rituximab in patients with previously untreated follicular lymphoma

André GoyJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USACorrespondence[email protected]

Mark BergerDeciphera Pharmaceuticals, Lawrence, KS, USA

Peggy FordJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA

Tatyana FeldmanJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA

Anthony MatoJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA

Colleen BejotJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA

Henry C. FungFox Chase Cancer Center, Temple University, Philadelphia, PA, USA

show all

Click to increase image sizeClick to decrease image size

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Sequential single-agent obatoclax mesylate (GX15–070MS) followed by combination with rituximab in patients with previously untreated follicular lymphoma

Information for

Open access

Opportunities

Help and information

Sequential single-agent obatoclax mesylate (GX15–070MS) followed by combination with rituximab in patients with previously untreated follicular lymphoma

Potential conflict of interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature